To access this element change to forms mode OFF
Grant Award View - GA30036
Developing an effective glycoconjugate vaccine against Group A...
GA ID:
GA30036
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
25-Oct-2018
Publish Date:
21-Dec-2018
Category:
Medical Research
Grant Term:
1-Jan-2019 to 31-Dec-2021
Value (AUD):
$324,914.30
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 17/18 1.1 Health and Medical Research
Grant Program:
Project
Grant Activity:
Developing an effective glycoconjugate vaccine against Group A Streptococcus causing rheumatic fever/heart disease
Purpose:
Globally Australian Aboriginal and Torres Strait Islanders have the highest recorded rate of Group A Streptococcus (GAS) infection, mainly rheumatic heart disease and rheumatic fever. GAS infection is endemic and often fatal due to post-infection problems.This project aims to develop a glycoconjugate vaccine to prevent GAS infection.We aim to avert these deaths by making a vaccine from small, specific parts of GAS proteins so the body makes safe antibodies that stop GAS and its related diseases.
GO ID:
GO Title:
NHMRC Project Grant Scheme
Internal Reference ID:
GNT1158748
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Queensland
Recipient ABN:
63 942 912 684
Grant Recipient Location
Suburb:
St Lucia
Town/City:
St Lucia
Postcode:
4072
State/Territory:
QLD
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
QLD
Postcode:
Country:
AUSTRALIA